Rigel Pharmaceuticals, Inc (RIGL)

Etorro trading 970x250
Rigel Pharmaceuticals, Inc (RIGL) Logo

About Rigel Pharmaceuticals, Inc

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. Address: 1180 Veterans Boulevard, South San Francisco, CA, United States, 94080

Rigel Pharmaceuticals, Inc News and around…

Latest news about Rigel Pharmaceuticals, Inc (RIGL) common stock and company :

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
22 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We're getting right into the week with a breakdown of the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Rigel to lay off 31, focus on later-stage drugs, including Covid program
15 Nov, 2021 Yahoo! Finance

The company is exiting early research and looking for "other opportunities" that complement its work in cancer.

Rigel Sharpens Focus on Its Advanced Portfolio Opportunities
15 Nov, 2021 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced plans to exit early-stage research and focus resources on its mid to late-stage development programs and its commercial efforts. The strategy will strengthen Rigel's ability to build value for shareholders by executing on the company's near-term value drivers: growing ITP sales, expanding the addressable market for TAVALISSE® (fostamatinib) with warm autoimmune hemolytic anemia (wAIHA) and COVID-19, advancing its wholly-owned IRAK1/4 prog

Rigel to Participate in Two Upcoming Investor Conferences
09 Nov, 2021 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in November:

When Will Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Breakeven?
04 Nov, 2021 Yahoo! Finance

Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) is possibly approaching a major achievement in its business, so we would...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
03 Nov, 2021 FinancialContent

Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market ...

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
03 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
03 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We're starting the day off right with a dive into the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

25 Stocks Moving in Wednesday's Pre-Market Session
03 Nov, 2021 FinancialContent

Gainers Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 56.4% to $26.20 in pre-market trading on the heels of three new ...

Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates
02 Nov, 2021 Yahoo! Finance

Rigel (RIGL) delivered earnings and revenue surprises of -20.00% and -10.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update
02 Nov, 2021 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2021, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Analysts Predict 76% Upside For LABU
02 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $104.75 per unit.

Earnings Scheduled For November 2, 2021
02 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per ...

Hedge Funds Are Crazy About Rigel Pharmaceuticals, Inc. (RIGL)
29 Oct, 2021 Yahoo! Finance

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update
26 Oct, 2021 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2021 financial results after market close on Tuesday, November 2, 2021. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08 Oct, 2021 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported the grant of stock options to purchase an aggregate of 469,000 shares of common stock to 23 newly hired employees. These awards were approved by the Compensation Committee of Rigel's Board of Directors and granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, with a grant date of October 7, 2021, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing

Peek Under The Hood: OMFS Has 21% Upside
29 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.67 per unit.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Investor Alert: Investigation over Potential Wrongdoing
27 Sep, 2021 FinancialContent

San Diego, CA -- (SBWIRE) -- 09/27/2021 -- Certain directors of Rigel Pharmaceuticals, Inc. are under investigation over possible breaches of fiduciary duties.

10 Top Penny Stocks To Watch This Week With Potential Biotech Catalysts
26 Sep, 2021 FinancialContent
Rigel to Participate in Three Upcoming Investor Conferences
02 Sep, 2021 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in September:

Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
01 Sep, 2021 Yahoo! Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in Clinical Infectious Diseases, an official publication of the Infectious Disease Society of America. The study was sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova Health System.

NASDAQ:RIGL Shareholder Notice: Investigation over Possible Securities Laws Violations by Rigel Pharmaceuticals, Inc.
30 Aug, 2021 FinancialContent

San Diego, CA -- (SBWIRE) -- 08/30/2021 -- An investigation was announced over potential securities laws violations by Rigel Pharmaceuticals, Inc. in connection with certain financial statements.

Why Did the FDA Reject Rigel's EUA Application for Its COVID-19 Therapy?
26 Aug, 2021 FinancialContent

More data is needed.

Analysts Forecast 19% Upside For OMFS
25 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $47.39 per unit.

Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations
18 Aug, 2021 Yahoo! Finance

Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL
17 Aug, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") (NASDAQ: RIGL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Rigel and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about ...

Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA
16 Aug, 2021 Yahoo! Finance

Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.

12 Health Care Stocks Moving In Friday's Intraday Session
13 Aug, 2021 FinancialContent

Gainers Biolase (NASDAQ:BIOL) stock increased by 38.01% to $0.87 during Friday's regular session. Trading volume for ...

Rigel Stock Falls After Update From COVID-19 Program
13 Aug, 2021 FinancialContent

The FDA has informedRigel Pharmaceuticals Inc(NASDAQ: RIGL) that data submitted in May from fostamatinib Phase 2 trial ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
13 Aug, 2021 FinancialContent

Gainers Biolase (NASDAQ:BIOL) stock moved upwards by 42.49% to $0.9 during Friday's pre-market session. The ...

Rigel Pharmaceuticals, Inc (RIGL) is a NASDAQ Common Stock listed in , ,

970x250